ProQr Therapeutics (PRQR) announced that the FDA has granted its QR-010 for Fast Track status for the treatment of cystic fibrosis (CF) patients who have the delta F508 mutation. QR-010 is an inhaled therapy designed to repair the genetic defect in RNA which will result in the synthesis of a normal healthy CFTR protein.